Related Experiment Video
Updated: Jul 5, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate
Robertino Mera1, Linda A Miller, Thomas R Fritsche
1GlaxoSmithKline, Research Triangle Park, North Carolina, USA. robertino.mera@gsk.com
Background:
The pneumococcal conjugate vaccine (PCV7), introduced in February 2000, covered 82% of the U.S. pediatric population in 2005. Changes over time in serogroup prevalence and multidrug-resistance (MR) to antimicrobials were evaluated using the U.S. SENTRY surveillance program.
Methods:
The study included 704 U.S. isolates, with equal numbers before (1998-1999) and after the introduction of the vaccine (2003-2004). Demographic data, serotype, and resistance profiles for five antimicrobial classes were analyzed. Strains displaying resistance to >or=2 classes were considered MR. Statistical analysis was performed using logistic regression.
Results:
Prevalence of PCV7 serotypes was 68.5% in the prevaccine years, dropping to 29.3% in the postvaccine period. Among PCV7 serotypes, only 19F persisted, with nonvaccine (NV) serotype 19nonF strains increasing from 3% to 20% of total p<0.001. NV serotypes were 1.9 times (95% confidence interval [CI] 1.1-3.1) more likely to acquire MR over time. Although PCV7 serotypes constituted 84% of all MR isolates in the prevaccine era, MR was unchanged in the postvaccine period due to increased prevalence and acquisition of resistance by NV serotypes. MR among invasive isolates did not change over time, but increased among noninvasive NV isolates by 17% (95% CI 12-22%).
Conclusions:
The complete switch in prevalence of PCV7 by NV serotypes has been aided by a herd effect in adults and older children. NV serotypes have acquired MR at a rate that is proportional to the replacement process.
Insights
The pneumococcal conjugate vaccine (PCV7) led to a decrease in vaccine-type serotypes, but nonvaccine serotypes increased and acquired multidrug-resistance (MR). This shift highlights the need to monitor evolving antimicrobial resistance patterns in Streptococcus pneumoniae.
Area of Science:
- Microbiology
- Epidemiology
- Vaccinology
Background:
- The heptavalent pneumococcal conjugate vaccine (PCV7) was introduced in the U.S. in 2000.
- PCV7 significantly impacted pediatric Streptococcus pneumoniae serotype prevalence.
Purpose of the Study:
- To evaluate changes in pneumococcal serogroup prevalence and multidrug-resistance (MR) over time.
- To assess the impact of PCV7 on antimicrobial resistance patterns.
Main Methods:
- Analysis of 704 U.S. Streptococcus pneumoniae isolates from before (1998-1999) and after (2003-2004) PCV7 introduction.
- Evaluation of serotype prevalence and resistance to five antimicrobial classes.
- Definition of MR as resistance to two or more antimicrobial classes.
Main Results:
- PCV7 serotype prevalence decreased from 68.5% to 29.3% post-vaccine.
- Nonvaccine (NV) serotypes, particularly 19nonF, increased significantly.
- NV serotypes were more likely to acquire MR, contributing to unchanged overall MR rates despite PCV7 use.
Conclusions:
- A shift from PCV7 to NV serotypes occurred, influenced by herd effects.
- NV serotypes are acquiring multidrug-resistance proportionally to their increased prevalence.
- Continuous surveillance is crucial to monitor evolving antimicrobial resistance in pneumococcal populations.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Atypical Pneumonia
Conjugation
Streptococcal Pharyngitis
Pneumonia I: Introduction
Viral Recombination

